GEN Exclusives

More »

GEN News Highlights

More »
Feb 6, 2007

KineMed and Bayer Healthcare to Discover New Therapeutic Applications for Candidates

  • KineMed and Bayer Healthcare signed an agreement to discover new therapeutic applications. "The collaboration with Bayer Healthcare is an important opportunity for us to discover new indications for promising compounds and to work with Bayer Healthcare to pursue clinical development,” comments David Fineman, president and CEO of KineMed.

    KineMed will identify new therapeutic utilities by applying its translational medicine technologies, AquaTag™ and KineMarker™. Once a disease target is established for a selected drug candidate, the companies will jointly determine the best development and commercialization path.

    “This is in fact,” points out Finemen, “the third indications discovery deal we have announced in the past year, each of which gives us the option to move into more advanced product development."


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

The Triple Package and Success

One theory for explaining “success," put forward by Amy Chua Jed Rubenfeld, posits cultural traits such as a superiority complex, personal insecurity and impulse control. Union College professors Joshua Hart and Christopher Chabris counter that intelligence, conscientiousness, and economic advantage are the most likely elements of success, regardless of ethnicity. Do you think that Hart-Chabris make a better argument for achieving success than the Chua-Rubenfeld theory?

More »